Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes—a Hellenic Cooperative Oncology Group (HeCOG) Trial — Αngelos Koutras (2020) | RDL Network
Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes—a Hellenic Cooperative Oncology Group (HeCOG) Trial
Article 2020 en
Authors
ΑK
Αngelos Koutras
FZ
Flora Zagouri
GK
Georgia-Angeliki Koliou
Abstract
1 min read
This phase II trial suggests that cabazitaxel is active as second-line treatment in taxane-pretreated patients with HER2-negative MBC, with manageable toxicity.
Αngelos Koutras, Konstantine T. Kalogeras, Meletios A Dimopoulos, Ralph M. Wirtz, Urania Dafni, Evangelos Briasoulis, Dimitrios Pectasides, Helen Gogas, Christos Christodoulou, Gerasimos Aravantinos, George Zografos, Eleni Timotheadou, Pavlos Papakostas, Helena Linardou, Evangelia Razis, Theofanis Economopoulos, Haralabos P. Kalofonos, George Fountzilas
Shahneen Sandhu, John Violet, Justin Ferdinandus, Sue-Ping Thang, Amir Iravani, Christina Guo, Grace Kong, Aravind Ravi Kumar, Timothy Akhurst, Alexis Beaulieu, Declan G. Murphy, Jennifer Mooi, Ben Tran, Guy C. Toner, Scott Williams, Rodney J. Hicks, Michael S. Hofman
Jim Janinis, George P. Stathopoulos, Paul Nikolaidis, Haralabos P. Kalofonos, Anna Kalogera‐Fountzila, E. Samantas, Gerasimos Aravantinos, Athanassios Anagnostopoulos, Christos Tolis, Thomas Makatsoris, S. Rigatos, Dimitrios Bafaloukos, Meletios A Dimopoulos, John Daniilidis, George Fountzilas
Discussion(0)
No comments yet. Be the first to comment.